For episode 25, we sit down with Dr. Paul Lammers, CEO of Triumvira Immunologics. Stay tuned to learn why having multiple programs in clinical trials can provide a safety net should one program fail and how it adds additional value for investors. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder & guest host Co-Founder, Andrew Brackin. Episodes launch weekly on Tuesdays & Thursdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.